Skip to Content

'
Elisabet E Manasanch, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2014 Duke University, Durham, NC, MHSc, Master of Health Sciences in Clinical Research
2005 University of Barcelona, Barcelona, Spain, MD, Medicine

Postgraduate Training

7/2013-3/2014 Clinical Fellowship, Multiple Myeloma Section, NCI - National Institutes of Health, Bethesda, MD
7/2010-7/2013 Clinical Fellowship, Hematology-Oncology, National Institutes of Health - NCI/NHLBI, Bethesda, MD
7/2007-7/2010 Clinical Residency Internal Medicine, The University of Massachusetts Medical School, Worcester, MD
11/2005-5/2007 Postgraduate Studies in Cell Biology of Cancer, University of Barcelona, Barcelona, Spain

Board Certifications

2013 Medical Oncology
2010 Internal Medicine

Honors and Awards

2016-2018 High Impact Clinical Research Support Program Award, MD Anderson Cancer Center
2015 Clinical Innovator Award, University of Texas MD Anderson Cancer Center
2014 Brian D. Novis Research Award, International Myeloma Foundation
2005 Agusti Pedro I Pons Foundation Grant for Postgraduate Studies, Agusti Pedro I Pons Foundation
2005 Honors in final clerkships: Pediatrics, Obstetrics/Gynecology, Psychiatry, Hematology and Neurology, University of Barcelona
2003 Catalan Society of Biology, Students' Award, Awarded by Jordi Pujol, president of Catalonia 1980-2003 (Spain)
2003 Erasmus-Socrates Europen Union Grant, Erasmus-Socrates Europen Union Program
2001 International Relations Office of the University of Barcelona Grant, University of Barcelona

Professional Memberships

American Society of Clinical Oncology
Member, 2010-present
American Society of Hematology
Associate Member, 2010-present
European Hematology Association
Junior Corresponding Member, 2012-present
International Myeloma Working Group
Member, 2013-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Alfaraj WA, Cachia D, Tummala S, Thomas SK, Manasanch EE. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia. Ann Hematol 95(2):347-348, 1/2016. e-Pub 10/2015. PMID: 26432713.
2. Cheah CY, Orlowski RZ, Manasanch EE, Oo TH. Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma. Ann Hematol 94(9):1605-7, 9/2015. e-Pub 6/5/2015. PMID: 26044891.
3. Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping L, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler-Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncol 1(6):746-54, 9/2015. e-Pub 7/2015. PMID: 26181891.
4. Manasanch EE, Salem DA, Yuan CM, Tageja N, Bhutani M, Kwok M, Kazandjian D, Carter G, Steinberg SM, Zuchlinski D, Mulquin M, Calvo K, Maric I, Roschewski M, Korde N, Braylan R, Landgren O, Stetler-Stevenson M. Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Leuk Lymphoma 56(5):1-24, 5/2015. e-Pub 10/2014. PMID: 25263319.
5. Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar S. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplant 50(5):668-72, 5/2015. e-Pub 3/2015. PMID: 25730192.
6. Burotto M, Manasanch EE, Wilkerson J, Fojo T. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist 20(4):400-10, 4/2015. e-Pub 3/20/2015. PMCID: PMC4391756.
7. Manasanch EE, Korde N, Mailankody S, Tageja N, Bhutani M, Roschewski M, Landgren O. Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. Haematologica 99(12):1769-71, 12/2014. PMCID: PMC4258744.
8. Zingone A, Wang W, Corrigan-Cummins M, Wu SP, Plyler R, Korde N, Kwok M, Manasanch EE, Tageja N, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Roschewski M, Zhang Y, Roccaro AM, Ghobrial IM, Calvo KR, Landgren O. Altered cytokine and chemokine profiles in multiple myeloma and precursor disease. Cytokine 69(2):294-7, 10/2014. e-Pub 7/2014. PMCID: PMC4148078.
9. Manasanch EE, Korde N, Zingone A, Tageja N, Fernandez de Larrea C, Bhutani M, Wu P, Roschewski M, Landgren O. The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma. Leuk Lymphoma 55(8):1707-14, 8/2014. e-Pub 1/2014. PMID: 24261677.
10. Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 99(6):e81-3, 6/2014. e-Pub 3/2014. PMCID: PMC4040899.
11. Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, Tageja N, Maric I, Mulquin M, Roschewski M, Kwok M, Liewehr D, Landgren O, Stetler-Stevenson M. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res 38(3):371-6, 3/2014. e-Pub 12/2013. PMCID: PMC3947595.
12. Tageja N, Manasanch EE, Korde N, Kwok M, Mailankody S, Bhutani M, Roschewski M, Landgren O. Smoldering multiple myeloma: present position and potential promises. Eur J Haematol 92(1):1-12, 1/2014. e-Pub 11/2013. PMID: 24112232.
13. Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Maric I, Calvo KR, Braylan R, Stetler-Stevenson M, Yuan C, Tembhare P, Zingone A, Costello R, Roschewski MJ, Landgren O. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma 54(10):2215-8, 10/2013. e-Pub 7/2013. PMID: 23311294.
14. Manasanch EE, Kristinsson SY, Landgren O. Etiology of Waldenström macroglobulinemia: genetic factors and immune-related conditions. Clin Lymphoma Myeloma Leuk 13(2):194-7, 4/2013. e-Pub 3/2013. PMID: 23473950.
15. Cherry BM, Costello R, Zingone A, Burris J, Korde N, Manasanch E, Kwok M, Annunziata C, Roschewski MJ, Engels EA, Landgren O. Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age. Am J Hematol 88(2):89-92, 2/2013. e-Pub 11/2012. PMID: 23169485.
16. Manasanch EE, Grivas P, Walter O, Davaro R. Kidney actinomycosis, a rare diagnosis that can mimic renal cell carcinoma: a case report and review of the literature. Infectious Diseases in Clinical Practice 20(5):362-364, 2012.
17. Manasanch EE, Smith JK, Bodnari A, McKinney J, Gray C, McDade TP, Tseng JF. Tumor registry versus physician medical record review: a direct comparison of patients with pancreatic neuroendocrine tumors. J Oncol Pract 7(2):111-6, 3/2011. PMCID: PMC3051856.
18. Villano JL, Collins CA, Manasanch EE, Ramaprasad C, van Besien K. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 7(5):436-8, 5/2006. PMID: 16648049.
19. Szekely AM, Bleichert F, Nümann A, Van Komen S, Manasanch E, Ben Nasr A, Canaan A, Weissman SM. Werner protein protects nonproliferating cells from oxidative DNA damage. Mol Cell Biol 25(23):10492-506, 12/2005. PMCID: PMC1291253.

Invited Articles

1. Manasanch EE. Thyroid hormones: turning up the heat in myeloma. Leuk Lymphoma 1-5(4):1-2, 4/2015. e-Pub 11/20/2014. PMID: 25315079.
2. Roschewski M, Manasanch EE, Wilson WH. Management of heavy chain diseases: the challenges of biologic heterogeneity. Oncology (Williston Park) 28(1):63-5, 1/2014. PMID: 24683720.

Abstracts

1. Shah J, Fend L, Manasanch E, Weber D, Thomas S, Turturro F, Shah N, Popat UR, Nieto Y, Bashir Q, Munoz S, Landry A, Mendoza K, Champlin RE, Qazilbash MH, Orlowski RZ. Impact of Induction Therapy on Outcomes in Newly diagnosed Myeloma Patients who received upfront Autologous Stem Cell Transplant and Maintenance Lenalidomide. American Society of Hematology Meeting, 12/2015.
2. Shah J, Feng L, Thomas S, Weber D, Wang M, Manasanch EE, Mendoza K, Orlowski RZ. Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood 126(23) (#376), 12/2015.
3. Shah JJ, Feng L, Manasanch EE, Weber D, Thomas SK, Turturro F, Shah N, Popat UR, Nieto Y, Bashir Q, Munoz SC, Landry A, Mendoza K, Champlin RE, Qazilbash MH, Orlowski RZ. Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomid/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. Blood 126(23) (#187), 12/2015.
4. Shah JJ, Feng L, Weber D, Thomas SK, Wang M, Turturro F, Qazilbash MH, Shah N, Bashir Q, Popat UR, Manasanch EE, Munoz SC, Landry A, Mendoza K, Nieto Y, Champlin RE, Orlowski RZ. Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood 126(23):3155-3155, 12/03/2015, 12/2015. e-Pub 12/2015.
5. Claussen CM, Chuang T, Shah J, Lee H, Shah N, Patel KK, Bashir Q, Parmar S, Thomas S, Qazilbash M, Davis RE, Neelapu SS, Weber D, Orlowski RZ, Feng L, Manasanch E. Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. Blood 126(23) (#5390), 12/2015. e-Pub 12/2015.
6. Manasanch EE, Claussen C, Dong W, Shah J, Lee H, Thomas S, Reed VK, Dabaja BS, Milgrom S, Pinnix CC, Parmar S, Shah N, Patel K, Bashir Q, Qazilbash M, Orlowski RZ, Feng L, Weber D. Clinical characteristics, outcomes and predictors of progression to multiple myeloma (MM) in 61 patients with solitary plasmacytoma. International Myeloma Workshop. Rome 15:e181-e182, 9/2015. e-Pub 9/2015.
7. Landgren O, Roschewski M, Mailankody S, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Zingone A, Costello R, Burton D, Zhang Y, Wu P, Carter G, Mulquin M, Zuchlinski D, Carpenter A, Gounden V, Morrison C, Maric I, Calvo KR, Braylan RC, MD4, Yuan C, Stetler-Stevenson M, Arthur DC, Lindenberg L, Karen K, Choyke P, Steinberg SM, Figg WD, Korde N. Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study. Blood 124:4746, 12/2014.
8. Bock FM, Lu G, Shah N, Bashir Q, Patel KK, Popat UR, Hosing CM, S, Korbling,M Delgado R, Rondon G, Orlowski RZ, Shah JJ,Manasanch EE, Champlin RE, Qazilbash MH. Clinical Characteristics and Outcomes in Patients with Multiple Myeloma and CKS1B Gene Gain/Amplification after Autologous Stem Cell Transplantation. Blood 124(21):2521, 12/2014.
9. Korde N, Mailankody S, Roschewski M, Faham M, Kotwaliwale C, Moorhead M, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Costello R, Zhang Y, Zingone A, Burton D, Mulquin M, Carpenter A, Zuchlinski D, Lamping E, Carter G, Morrison C, Kurdziel K, Lindenberg M, Kurlander R, Maric I, Calvo KR, Braylan RC, Yuan C, Stetler-Stevenson M, Arthur DC, Steinberg SM, Figg WD, Choyke PLandgren O. Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities. Blood 124(21) (#2105), 12/2014.
10. Shah JJ, Feng L, Manasanch EE, Weber DM, Thomas SK, Turturro F, Alexanian R, Nina Shah N, Popat UR, Qaiser YN, Bashir Q, Qazilbash MH, Champlin RE, Orlowski RZ. Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. Blood 124(21):33, 12/2014.
11. Bhutani M, Turkbey B, Tan E, Korde N, Kwok M, Manasanch EE, Tageja N, Mailankody S, Roschewski MJ, Mulquin M, Lamping E, Weiss BM, Mena E, Lindenberg L, Calvo KR, Maric I, Choyke PL, Kurdziel KA, Landgren O. Focal bone marrow processes and early bone lesions in patients with multiple myeloma (MM) precursor diseases: A prospective study using molecular imaging. American Society of Clinical Oncology 32(5s) (#8587), 6/2014.
12. Dosani T, Korde N, Manasanch EE, Tageja N, Mailankody S, Roschewski MJ, Kwok M, Kazandjian DG, Landgren O, Maric I. Large granular lymphocyte (LGL) subsets in smoldering multiple myeloma (SMM): Immunophenotypic profiles that predict progression to multiple myeloma (MM). American Society of Clinical Oncology 32(5s) (#8587), 6/2014.
13. Tageja N, Wang W, Plyler R, Corrigan-Cummins M, Korde N, Manasanch EE. Altered cytokine profiles in multiple myeloma (MM) and precursor disease: Predictors of progression and potential targets for treatment. Journal of Clinical Oncology 31(15) (#8597), 6/2013.
14. Manasanch EE, Korde N, Yuan C, Kwok M, Tageja N, Bhutani M, Flanders AW, Zingone A, Costello R, Tembhare P, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Steinberg SM, Roschewski MJ, Landgren O, Braylan R, Stetler-Stevenson M. Biological variations of plasma cells in the bone marrow of smoldering multiple myeloma (SMM) and multiple myeloma (MM) patients: multiple biopsies in the same patient. Journal of Clinical Oncololgy 31(15) (#e19506), 6/2013.
15. Landgren O, Mailankody S, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Zingone A, Costello R, Burton D, Zhang Y, Wu P, Carter G,Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan RC,Yuan C,Stetler-Stevenson M, Arthur DC, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Roschewski M, Korde N. Clinical and Correlative (Phase II) Pilot Study – Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (Dex) in High Risk Smoldering Multiple Myeloma (“Early Myeloma”). Blood 122(21) (#1939), 2013.
16. Landgren C, Zingone A, Kwok M, Manasanch EE. Clinical and correlative pilot study of carfilzomib, lenalidomide and dexamethasone followed by lenalidomide extended dosing (CRD-R) in high risk smoldering multiple myeloma. IMWG Khyoto, Japan, 2013.
17. Korde N, Zingone A, Kwok M, Manasanch EE. Combination CRd therapy followed by extended LEN dosing in newly diagnosed MM patients shows deep response rates corroborated by MRD assays and tolerable side effects. EHA (#B4823), 2013.
18. Manasanch EE, Fernandez C, Zingone A, Korde N, Tageja N, Bhutani M, Kazandjian D, Wu P, Costello R, Burton D, Carter G, Zuchlinski D, Mulquin M, Maric I, Calvo KR, Yuan C, Stetler-Stevenson M, Roschewski M, Landgren O. Enzymatic activity of circulating plasma proteasomes (cProt) in newly diagnosed multiple myeloma (NDMM) patients undergoing treatment with carfilzomib, revlimid and dexamethasone (CRd). Blood 122(21) (#651), 2013.
19. Mailankody S, Korde N, Faham M, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Weng L, Moorhead M, Costello R, Zhang Y, Zingone A, Burton D, Wu P, Mulquin M, Zuchlinski D, Kurlander R, Maric I, Calvo KR, Braylan RC, Yuan C, Stetler-Stevenson M, Arthur DC, Roschewski M, Landgren O. Molecular sequencing for minimal residual disease (MRD) detection in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Blood 122(21) (#1902), 2013.
20. Bhutani M , Korde N, Kwok M, Manasanch EE. Normalization of serum free light chain (sFLC) ratio as a biomarker for negative minimal residual disease (MRD) in patients treated with carfilzomib, lenalidomide and dexamethasone followed by lenalidomide maintenance (CRd-R) for newly diagnosed myeloma. Blood 122(21) (#653), 2013.
21. Manasanch EE, Jordan E, Korde N. Plasma cell proliferation fraction and the risk of progression from smoldering multiple mieloma (SMM) to multiple mieloma (MM). EHA (#B1495), 2013.
22. Fernández de Larrea C, Zingone A, MD, Manasanch EE, Korde N, Wu P, Costello R, Zuchlinski D, Mulquin M, Burton D,Maric I, Calvo KR, Stetler-Stevenson M, Yuan C, Roschewski M, Landgren O. Plasma circulating proteasomes as biomarkers along natural history of asymptomatic monoclonal gammopathies. Blood 122(21) (#3133), 2013.
23. Korde N, Espana K, Manasanch EE. Uninvolved Heavy-light-chain Pair Suppression (UHLCPs) in Smoldering Myeloma: New Insights. IMWG Kyoto, Japan, 2013.
24. Kwok ML, Korde N, Manasanch EE, Flanders AW, Maric I, Calvo KR, Zingone A, Costello R, Cordaro D, Sato A, Mulquin M, Zuchlinski D, Roschewski M, Landgren O. Altered plasma cell characteristics in smoldering myeloma and MGUS patients preceding immune-related conditions. Blood 120(21) (#4006), 11/2012.
25. Korde N, Liu QY, Kwok M, Manasanch EE, Simakova O, Mailankody S, Roschewski M, Zingone A, Costello R, Zuchlinski D, Mulquin M, Calvo KR, Braylan RC, Maric I, Landgren O. Early myelodysplastic changes present in substantial proportion of monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM) patients. Blood 120(21) (#1805), 11/2012.
26. Tembhare PR, Yuan C, Korde N, Manasanch EE, Kwok M, Roschewski M, Maric I, Calvo KR, Mulquin M, Zuchlinski D, Landgren O, Stetler-Stevenson MA. Peripheral blood involvement with minimal disease is common in multiple myeloma but not in smoldering myeloma. Blood 120(21) (#4994), 11/2012.
27. Korde N, Zingone A, Kwok M, Manasanch EE, Costello R, Zuchlinski D, Mulquin M, Maric I, Calvo KR, Braylan RC, Yuan C, Tembhare PR, Stetler-Stevenson M, Arthur DC, Raffeld M, Xi L, Choyke P, Kurdziel K, Lindenberg, L Steinberg SM, Roschewski M, Landgren O. Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients. Blood 120(21) (#732), 11/2012.
28. Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Yancey MA, Mulquin M, Maric I, Calvo KR, Braylan R, Stetler-Stevenson M, Yuan C, Tembhare P, Zingone A, Costello R, Roschewski MJ, Landgren O. A prospective clinical study evaluating current models for risk of progression from smoldering multiple myeloma (SMM) to multiple myeloma (MM). Journal of Clinical Oncology 30(15) (#8088), 5/2012.
29. Korde N, Zingone A, Kwok M, Manasanch EE, Bhutani M, Costello R, Yancey MA, Mulquin M, Calvo KR, Maric I, Tembhare P, Yuan C, Stetler-Stevenson M, Arthur DC, Choyke PL, Kurdziel KA, Steinberg SM, Raffeld M, Roschewski MJ, Landgre O. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients. Jounal of Clinical Oncology 30(15) (#e18568), 5/2012.
30. Kwok M, Korde N, Manasanch, Bhutani M, Maric I, Calvo KR, Zingone A, Costello R, Cherry BM, Yancey MA, Mulquin M, Roschewski MJ, Landgren O. Role of immune-related conditions in smoldering myeloma and MGUS. Journal of Clinical Oncology 30(15) (#8104), 5/2012.
31. Korde N, Zingone A, Kwok M, Manasanch EE, Costello R, Zuchlinski D, Mulquin M, Maric I, Calvo KR, Braylan RC, Yuan C, Tembhare PR, Stetler-Stevenson M, Arthur DC, Raffeld M, Xi L, Choyke P, Kurdziel K, Lindenberg L, Steinberg SM, Roschewski M, Landgren O. Phase II clinical and correlative study of carfilzomib, lenalidomide and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients. J Clin Oncol 30(15) (#suppl, abstr e18568), 2012.
32. Manasanch EE, Wilkerson J, Xiu L, Zhuang S, Bates S, Stein W, Fojo AT. Assessment of Tumor Growth (g) and Regression (d) Rate Constants in Patients with Multiple Myeloma (MM) Shows That the Superiority of Bortezomib with Liposomal Doxorubicin (PLD+B) Over Bortezomib Alone (B) Is a Result of Reduced Growth of Refractory Tumor Cells and Not of Higher Regression Rates, and Provides An Earlier Efficacy Endpoint That Allows for Comparison Across Trials. Blood 118(21):5113 (#5113), 11/2011.
33. Manasanch EE, Mcdade TP, Bodnari A, et al. Tumor registry versus physician medical record review: a head-to-head comparison of malignant pancreatic neuroendocrine tumor (mPNET) cases. Journal of Clinical Oncology 27(15s) (#suppl abstr 6600), 2009.
34. Hu B, Sasaki K, Bashir Q, Shah N, Patel KK, Popat UR, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen JL, Shah JJ, Manasanch EE, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH,. Depth of response post autologous hematopoietic stem cell transplantation (auto-HCT) to predict outcome in high risk multiple myeloma (MM). 2016 ASCO Annual Meeting (#8019). Submitted.
35. Mailankody S, Korde N, Roschewski MJ, Christofferson A, Boateng M, Zhang Y, Manasanch EE, Kazandjian DG, Kwok M, Bhutani M, Tageja N, Zingone A, Costello R, Lamy L, Hultcrantz M, Papaemmanuil E, Stetler-Stevenson M, Figg WD, Keats JJ, Landgren O,. Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients. 2016 ASCO Annual Meeting (#8003). Submitted.
36. Mathur R, Manasanch E, Shah J, Weber D, Thomas S, Lee HC, Davis E, Orlowski R, Neelapu SS. Immune escape mechanisms associated with early progression from smoldering multiple myeloma to symptomatic multiple myeloma. 2nd Annual Immuno-therapy in Myeloma Scientific Workshop, Boston, MA. Submitted.

Book Chapters

1. Lee HC, Patel K, Kongtim P, Parmar S, Lin P, Qazilbash MH, Thomas S, Manasanch EE. Multiple Myeloma and Other Plasma Cell Dyscrasias. In: MD Anderson Manual for Medical Oncology, 3rd. McGraw Hill, 2015. ISBN: 978-0071847940.
2. Manasanch EE, Tageja N, Landgren O. Multiple Myeloma. In: Bethesda Handbook of Clinical Hematology, 3rd, 2013. ISBN: 978-1-4511-82705.
3. Manasanch EE, Lozier J. Venous Thromboembolism. In: Bethesda Handbook of Clinical Hematology, 3rd, 2013.

Letters to the Editor

1. Manasanch EE, Braylan R, Stetler-Stevenson M, Yuan C, Gounden V, Korde N, Tageja N, Bhutani M, Calvo K, Maric I, Roschewski M, Staudt LM, Landgren O. Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma. Leuk Lymphoma 55(6):1402-3, 6/2014. e-Pub 12/2013. PMID: 23915224.
2. Manasanch EE, Freeman AF, Pittaluga S, Costello R, Holland SM, Landgren O. Serum free light chains as predictors of lymphomagenesis in patients with autosomal dominant hyper-immunoglobulin E syndrome (Job's syndrome). Leuk Lymphoma 54(6):1316-7, 6/2013. e-Pub 11/2012. PMID: 23039380.

Last updated: 6/2/2016